

epilepsydesireproject.eu

Call Identifier: F7-health-2013-Innovation-1
Project ID: Health-F2-602531-2013
Date of the EC Grant
Agreement Signature: 22 July 2013
Start date: 1 October 2013
End date:September 2018
Duration: 60 Months
Total Project cost: €16,957,461.09

Total Project EC Funding: €11,995,646.00





Strategies for Innovative Research to Improve Diagnosis, Prevention and Treatment In Children with Difficult to Treat Epilepsy

DESIRE project coordinator: Prof Renzo Guerrini,
Dipartimento di Neuroscienze, Universita degli Studi di Firenze, Italy
renzo.guerrini@unifi.it

Many childhood epilepsies, especially severe forms, result from a complex combination of an epileptogenic process and a developmental process, which are thought to influence each other.

WP Dissemination and Exploitation: Prof Janet Mifsud Department of Clinical Pharmacology and Therapeutics, University of Malta janet.mifsud@um.edu.mt







Why EED?

- A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle.
- EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cognitive and behavioral impairments.
- EDD are the most frequent drug-resistant pediatric epilepsies carrying a lifelong perspective of disability and reduced quality of life.
- Although EDD collectively represent a major medical and socio-economic burden, their molecular diagnosis, pathogenic mechanisms (PM) and rationale treatment are poorly understood.







What are the objectives of DESIRE?

To advance the state of the art with respect to:

- the genetic and epigenetic causes and PM of EDD, particularly epileptogenic MCD
- to elucidate molecular networks and disrupted protein complexes and search for common bases for these apparently heterogeneous disorders.
- To develop and use diagnostic tools (biomarkers) and protocols through the study of a unique and well-characterized cohort of children to provide standardized diagnosis for patient stratification and research across Europe.
- To develop treatments for EDD using randomized, multidisciplinary clinical protocols and test preclinical strategies in experimental models which address novel preventative strategies.







How do we collaborate?

Identification of causative genes for MCDs, EDD and of possible epigenetic alterations in FCD pathogenesis. (P1, P3, P4, P15)



Functional experiments in animal and cellular models and in human brain slices (P3, P8, P10)

> Development of new diagnostic tools and biomarkers (P1, P2, P4, P14, P15, P18,P19,P20)

Data Safety Monitoring Board



Randomized Clinical trial Cure FCD (P12, P13)

Innovative therapeutic strategies to treat seizures and prevent epilepsy (P3, P6, P7,P17,P21)

Identification of genetic causes and pathophysiological mechanisms of specific EE models (P1, P2, P5, P6, P7, P9, P14, P24, P25)

> Strategies for Innovative Research to Improve Diagnosis, Prevention and Treatment In Children with Difficult to Treat Epilepsy







DESIRE in numbers

- 5 years project starting the 1st October 2013 Last year 2018
- 28 partners (last submitted amendment)
- 8 Third Parties
- 9 countries
- 2.227,29 man/months
- > 250 researchers





Who are we?

UNIVERSITA TA MALTA

DI.V.A.L. TOSCANA SRL

MICROMED S.P.A.

CEGAT GMBH

VARIONOSTIC GMBH

AMARNA THERAPEUTICS BV

ISTITUTO GIANNINA GASLINI

UNIVERSITE D'ANGERS

vviio are vve.

UNIVERSITA DEGLI STUDI DI FIRENZE (co-ordinator)

FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

UNIVERSITAETSKLINIKUM ERLANGEN

UNIVERSITA DEGLI STUDI DI VERONA

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

ISTITUTO ITALIANO DI TECNOLOGIA

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

KING'S COLLEGE LONDON

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

KLINIKUM DER UNIVERSITAET ZU KOELN

UNIVERSITY COLLEGE LONDON

UNIVERSITE LIBRE DE BRUXELLES

UNIVERSITA TA MALTA

THE UNIVERSITY OF LIVERPOOL

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED

Improve Diagnosis, Prevention and Treatment In Children with Difficult to Treat Epilepsy

Strategies for Innovative Research to

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL

UNIVERSITA CATTOLICA DEL SACRO CUORE

OSPEDALE PEDIATRICO BAMBINO GESU



Thank you!





